The obtained data show that venetoclax has been combined, for AML treatment in AYA cases, with various agents: cytarabine, azacytidine, decitabine, idarubicin, fludarabine, cladribine, selinexor, filgrastim, cedazuridine, revumenib, gemtuzumab ozogamicin, gilteritinib, sorafenib, midostaurin, Mcl-1 inhibitors, CDK inhibitors, and arsenic. This evidence concerns the gene MCL1 and acute myeloid leukemia.